BRD2 and infection: In Africa, Karim et al.35 were the first to propose such a strategy; yet even in a high risk setting such as described by Gous et al.,36 pooled NAT would still be relatively expensive per additional case detected, as very few patients will be in the NAT-positive antibody-negative stage of recent infection.37 More recently, a study by Dowling et al.38 demonstrated that DBS can be used for this purpose, which would facilitate its wide implementation in RLS.